Systemic lupus erythematosus (SLE) is a heterogeneous disease with respect to disease manifestations, disease progression and treatment response. Therefore, strategies to identify biomarkers that help distinguishing SLE subgroups are a major focus of biomarker research. We reasoned that a multiparametric autoantibody profiling approach combined with data mining tools could be applied to identify SLE patient clusters. We used a bead-based array containing 86 antigens including diverse nuclear and immune defense pathway proteins. Sixty-four autoantibodies were significantly (p < 0.05) increased in SLE (n ¼ 69) compared to healthy controls (HC, n ¼ 59). Using binary cut-off thresholds (95% quantile of HC), hierarchical clustering of SLE patients yields five clusters, which differ qualitatively and in their total number of autoantibodies. In two patient clusters the overall accumulated autoantibody reactivity of all antigens tested was 31% and 48%, respectively. We observed a positive association between the autoantibody signature present in these two patient clusters and the clinical manifestation of glomerulonephritis (GLMN). In addition, groups of autoantibodies directed against distinct intracellular compartments and/or biological motifs characterize the different SLE subgroups. Our findings highlight the relevant potential of multiparametric autoantibody detection and may contribute to a deeper understanding of the clinical and serological diversity of SLE. Lupus (2016) 25, 812-822.
Introduction
Systemic lupus erythematosus (SLE) is a heterogeneous, inflammatory, multisystem autoimmune disease, which follows a relapsing and remitting course. Patients with SLE vary with regard to their disease course, disease manifestations and responsiveness to therapy. 1 A common serological feature of SLE is the production of autoantibodies directed against nuclear antigens like DNA (anti-dsDNA autoantibodies), DNA-binding proteins (i.e. histones), RNA binding proteins (i.e. anti-U1-snRNP autoantibodies), cytoplasmic and extracellular, as well as miscellaneous proteins (summarized in Table 2 ). 2, 3 It is presumed that an increased rate of apoptosis and the formation of neutrophil extracellular traps (NETs) generates neoantigens on proteins, which may be recognized as autoantigens in SLE. 4 Indeed, a great number of antinuclear autoantibodies (ANA) and anti-neutrophil cytoplasmic antibodies (ANCAs) found in SLE patients are directed against NET components and components of apoptotic blebs. 5 Over the past decades more than 180 different autoantibody specificities have been reported in SLE, 3 which greatly differ in their diagnostic sensitivity and specificity, association with clinical manifestations, disease activity and ethnicity. 2 Current diagnostic methods for determining autoantibodies in SLE have mainly focused on a relatively small set of autoantibody targets of which anti-dsDNA, anti-phospholipid and anti-Sm are important criteria for the clinical diagnosis and classification of SLE. 6, 7 The autoantibody profile is usually determined by ELISA, line immunoassay (LIA) methods, addressable laser bead assays (ALBIA), chemiluminescence immunoassays (CIA) and fluorescence immunoassays (FEIA). 8 As these methods are usually restricted to a small set of analytes, they fall short to exploit the great number of available autoantibody targets in SLE. In contrast, multiplexing technologies, such as the Luminex xMAP technology, enable the simultaneous detection of a larger number of autoantibody targets in a single serum sample and may provide deeper insights into the underlying pathophysiology of SLE. We hypothesized earlier that a set of novel autoantibody specificities in conjunction with welldescribed autoantibody targets have the potential to characterize SLE subgroups based on substantially diverse autoantibody reactivities. Those subgroups shall be interrogated as to whether their clinical manifestations or clinical course are different.
Here we describe the application of a bead-based 86 antigen array that includes a combination of well-described autoantibody targets as well as novel autoantigens previously identified by us in large-scale autoantibody profiling studies. 9 We analyzed the autoantibody reactivity profile of 69 SLE patients and 59 healthy controls (HC). Based on their autoantibody reactivity pattern and the total number of autoantibodies identified in these patients, the SLE cohort might be decomposed into five clusters of which two were enriched with SLE patients with glomerulonephritis (GLMN).
Material and methods

Study subjects
Serum samples of SLE patients were collected at the Heinrich-Heine-University Du¨sseldorf (HHUD) and stored at À80 C until use. All individuals provided written informed consent and the study was approved by the Ethics Committee of the Medical Faculty HHUD (study No 2546). At the time of serum sample collection, patient information on demographics, disease severity and (organ) damage were assessed using the Systemic Lupus Activity Measure (SLAM) 10 and/or the Systemic Lupus International Collaborating Clinics (SLICC) Damage Index. 11 All SLE patients fulfilled the American College of Rheumatology (ACR) classification criteria for SLE, respectively. 6, 12 Lupus nephritis was present at any time prior to sampling. The patient's ethnicity was recorded. ANA were tested by indirect immunofluorescence (Euroimmun, Luebeck, Germany), a titer >1:80 was considered positive. HC were chosen from a pool of specimens of blood donors of the Bavarian Red Cross (Munich, Germany) to match the age and gender of SLE patients. Ethical approval from the ethical committee of Bayerische Landesa¨rztekammer was obtained (Study No. 01/09). Subject demographics and characteristics and ANA testing are summarized in Table 1 .
Luminex autoantibody array design
International guidelines to classify SLE as well as the existing considerable amount of scientific literature were first surveyed to identify autoantibodies and their target antigens known to be reactive in SLE and other systemic autoimmune diseases, including systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjo¨gren's syndrome (SjS), mixed connective tissue disease (MCTD) and idiopathic inflammatory myopathies (IIM). 2, 3, [13] [14] [15] [16] From our antigen array, to our best knowledge, 50 autoantibody targets have been previously associated with SLE or other systemic autoimmune diseases. A further 36 novel autoantibody targets were identified in large-scale autoantibody screening studies at our labs using human cDNA libraries 9 to generate over 7000 human proteins and will be described in detail elsewhere (manuscript in preparation).
A total of 86 antigens were selected for this study and referred to as ''NavigAID SLE'' array using Luminex FlexMAP 3D technology. The selected analytical targets can be grouped into different functional protein families or belong to immune-relevant biological pathways (Table 2) . Certain antigens were sourced from vendors providing antigens for IVDassay development. The following antigens were purchased from Diarect AG (Freiburg, Germany): U1-snRNP68/70 kDa (SNRNP70), U1-snRNP A (SNRPA), U1-snRNP C (SNRPC), U1-RNP B/B 0 (SNRPB), SmD3 (SNRPD3), ribosomal phosphoprotein P0 (RPLP0), ribosomal phosphoprotein P1 (RPLP1), Ku (p70/p80), CENPB, DNA topoisomerase I (TOP1, Scl-70), SSA/Ro52 (TRIM21), myeloperoxidase (MPO), SSB/La, and PDC-E2 (DLAT). All other antigens were produced inhouse using E.coli SCS1 carrying plasmid pSE111, containing an N-terminally located hexa-histidinetag. 17 Antigens were affinity-purified under denaturing conditions using Protino Õ Ni-IDA 1000 funnel columns (Macherey-Nagel, Du¨ren, Germany). 18 Furthermore, a 947 base pair dsDNA PCR fragment was produced, which harbours a primary amino group at the 5 0 end, and included in the array. Each antigen was coupled to magnetic carboxylated colour-coded beads (MagPlex TM microspheres, Luminex Corporation, Austin, Texas). The manufacturer's protocols were adapted to enable multiplexing using semi-automated procedures. All liquid handling steps were carried out by either an eight-channel pipetting system (Starlet, Hamilton Robotics, Bonaduz, Switzerland) or a 96-channel pipetting system (Evo Freedom 150, Tecan, Ma¨nnedorf, Switzerland). For each coupling reaction, up to 12.5 mg antigen and 8.8 Â 10 5 MagPlex TM beads per colour were used. Beads were resuspended in 120 ml activation buffer (100 mM NaH 2 PO 4 , pH 6.2) and activated by adding 15 ml 1-ethyl-3-(3-dimethlyaminopropyl) carbodiimide (50 mg/ml) and 15 ml Nhydroxy-succinimide (50 mg/ml) for 20 min. Activated beads were washed three times and resuspended with 50 mM 2-(N-morpholino)ethanesulfonic acid (MES), pH 5.0. Coupling of antigen was performed for 2 h at room temperature (RT). Coupled beads were washed and resuspended in blocking buffer (phosphate buffered saline (PBS), 1% bovine serum albumin (BSA), 0.05% ProClin300). Finally, beads were combined and stored at 4-8 C until use.
Autoantibody profiling
Serum samples were diluted 1:100 in assay buffer (PBS, 0.5% BSA, 50% Low-Cross buffer (Candor Biosciences, Wangen, Germany), added to the bead mix and incubated for 20 h at 4-8 C. After washing with PBS/0.05% Tween20 the beads were incubated with the R-phycoerythrin-labelled detection antibody (5 mg/ml, goat anti-human or goat-antimouse IgG, Dianova, Hamburg, Germany) for 45 min at RT. The beads were washed and then resuspended in 100 ml sheath fluid (Luminex Corporation, Austin, Texas). Subsequently, beads were analyzed in a FlexMap3D instrument (Luminex Corporation, Austin, Texas). The IgG reactivity values are given as median fluorescence intensity (MFI) and antigens fulfilling the minimum bead count criterion (>30 beads measured per bead ID) were exported for data analysis.
Data analysis
Data processing and analysis were performed using R (http://www.r-project.org/ version 3.0.1) and KNIME Table 2 Composition of NavigAID SLE Antigen Array Category Autoantibody Autoantigen Gene ID 
Results
Subject characteristics
A total of 69 Caucasian SLE patients from Germany and 59 healthy blood donor samples were analyzed and as best possible matched for age and gender. Thirty-one (45%) SLE patients had clinical manifestation of GLMN. Demographics, ANA testing on HEp cells, SLAM and SLICC are shown in Table 1 .
Diagnostic utility of the selected analytical targets
First, the usefulness of single autoantibody markers to distinguish all SLE patients as a group from healthy control subjects was analyzed. A Mann-Whitney U-test including Bonferroni correction for multiple testing and ROC analysis was performed and resulted in a total of 64 autoantibodies (p < 0.05) that were statistically significantly elevated in SLE samples compared to HC (Table 3) . Highly significant markers include the most commonly measured autoantibody reactivities in SLE such as dsDNA and Sm (SmD3, SNRPB).
Novel reactivities to antigens from different protein categories (Table 2) such as B-cell receptor-associated protein 31 (BCAP31), BTB/POZ domaincontaining protein 7 (BTBD7), major vault protein (MVP), Non-POU domain-containing octamerbinding protein (NONO/NRB54) and thymopoietin (TMPO) were viewed as valid extensions of current knowledge about the vast SLE autoantibody repertoire. In addition, the prevalence of autoantibodies in SLE was calculated by applying the 95% quantile of the HC samples as a cut-off level for autoantibody positivity in SLE ( Table 3) . Eleven of 86 autoantibodies had prevalence values greater than 50% in our SLE cohort. In more detail, six of these autoantibodies target common SLE autoantigens including dsDNA, ribosomal protein P (RPLP1, RPLP2, RPLP0), Sm proteins (SmD3, SNRPB) and Ku (p70/p80). Further, four autoantigens have, to our knowledge, not yet been described as prominent targets in SLE and comprise BCAP31 (59%), TMPO (55%), EH-domain containing 1 (EHD1, 55%) and mucin-1 (MUC1, 51%). Among the autoantibodies tested, 70% of all SLE patients tested positive for anti-dsDNA autoantibodies in our assay. In summary, there was a broad range of prevalence rates from 7% to 70% for autoantibodies in our SLE cohort but, as expected, no single marker was capable of positively classifying all SLE patients alone.
Multivariate analysis
A PCA was carried out using a log 2 transformed dataset of autoantibody reactivities in SLE and HC samples. Figure 1 shows a score-plot representing the first two principal components of all samples, which relate to 37.7% and 6.2% of the variance, respectively. The samples were segregated into two main clusters separating HC from SLE samples. Using this unsupervised method only a few SLE samples were interspersed with healthy samples due to low autoantibody reactivities. No apparent patient clustering could be achieved by PCA. A weak segregation of patients with GLMN was found, whereas SLICC and SLAM scores could not be segregated (not shown).
The qualitative analysis of autoantibodies present in an individual is a pivotal aspect of determining the autoantibody reactivity pattern in SLE patients and patient subgroups facilitating data analysis. For a qualitative cluster analysis, the autoantibody reactivity values were converted into binary data using the 95% quantile threshold of HC. For each patient the absolute number of ''positive'' markers was calculated. In addition, the overlap between the antigen signatures of patients was investigated by hierarchical cluster analysis ( Figure 2 ) using the Ward algorithm and Manhattan distance as a similarity measure. 19 It could be shown that the pairwise comparison of the shared signature allows SLE subgroups to be visualized. A number of five patient clusters representing the highest inter-distance cluster measure was chosen for further characterization (Figure 2 ). The lowest reactivity was found in cluster ''yellow'', which contains five SLE patients, who were only reactive on average with 8% of the total number of antigens tested. In striking contrast, the 14 patients in cluster ''red'' tested positive for 50% of all antibodies tested in the array.
For an interpretation, we evaluated whether the five reactivity clusters could be matched to available clinical manifestations. There were a total of 31 patients (45%) in our SLE cohort who were diagnosed SLE together with GLMN as an important disease outcome. 20 Figure 2 shows that clusters ''red'' (n ¼ 8, 57%) and ''blue'' (n ¼ 14, 67%) were compared to clusters ''green'' (n ¼ 5, 29%), ''yellow'' (n ¼ 0) and ''magenta'' (n ¼ 4, 33%) enriched in SLE patients with GLMN.
We then examined the autoantibody reactivity pattern of each cluster and generated a heat map (Figure 3) . Table 3 lists the number of SLE patients tested positive for each antigen per cluster. It became evident that the clusters show partially overlapping autoantibody reactivity but also differ qualitatively in particular autoantibody subclusters. In cluster ''blue'', the four most frequent autoantibody targets were RPLP0, RPLP2, SmD3 and dsDNA. As shown before in Figure 3 , this includes the largest number of SLE patients and the highest prevalence of the clinical manifestation GLMN. Compared to cluster ''red'', cluster ''blue'' also contains a unique set of autoantibody reactivities, including novel ones to proteins involved in apoptotic processes (HSPE1, HIP1, and FAF1), transcription regulation (SSX2 and NRBF2), FBXO22 and IL-6. Interestingly, further autoantibody reactivities were found such as fascin-1 (FSCN1), a protein biomarker of inflammatory dendritic cell infiltrates in myositis muscles 21 and EXOSC10, which is the polymyositis and dermatomyositis antigen 2 PM/Scl100. 22 Cluster ''red'' can be distinguished from all other clusters by reactivity to a set of antigens implicated in immune/defense pathways, including the neutrophilic granule proteins LYZ, CTSG, PRT3 and ELANE as well as LMNA, AARS (PL-12), HIST1H4A and HNRNPM. Another autoantibody set with highest reactivity in cluster ''red'' included among the well-known SSA antigens TRIM21 (Ro52), TROVE2 (Ro60) and a member of the histone H2 protein family (HIST3H2AA3), three novel autoantigens: plasmalemmal vesicle-associated protein (PLVAP), BST2 and NONO/NRB54. SLE patients in clusters ''green'' and ''magenta'' can be characterized as having an overall lower number of autoantibody reactivities compared to clusters ''blue'' and ''red''. The predominant autoantibody reactivity of cluster ''green'' contains TMPO, RPLP0, BCAP31 and SmD3, whereas the three most frequent autoantibodies in cluster ''magenta'' were RPLP0, dsDNA and RPLP2. Compared to all other patient clusters, cluster ''yellow'' represents patients with very low autoantibody reactivity, who tested negative for antihistone (HIST1H4A, HIST2H2AA3 and HIST2H2BE) and anti-Sm (SmD3 and SNRPB) autoantibodies. However, patients in cluster ''yellow'' mainly tested positive for autoantibodies against SSA/Ro52 (TRIM21), SSA/Ro60 (TROVE2), SSB/La, U1-snRNP (SNRNP70 and SNRPA) and dsDNA, only.
Discussion
Given the complexity and heterogeneity of SLE, the search for biomarkers that help to distinguish subgroups of SLE patients is a major focus of biomarker research in SLE. Several novel biomarker strategies have been applied as tools to improve the clinical management of SLE and include the characterization of gene signatures, autoantibody profiles and leukocyte surface markers. 23 In particular, a signature of activated interferon alpha (INFa) pathway genes, which is related to increased disease activity has recently gained considerable interest. 24 From these studies, it has become apparent that marker signatures are useful to account for the considerable clinical diversity of SLE, which can be appropriately addressed by multiplexed, multimarker approaches. 23 The validation and assay development of such multimarker signatures is certainly challenging and requires a sufficiently robust technical platform. Ideally, it can be placed in many labs with similar performance. So far, over 180 autoantibody specificities have been described in SLE and provide a readily accessible source of biomarkers for establishing the concept of subgrouping SLE based on biomarker signatures. 3 A major tool often used in published autoantibody profiling studies are planar protein arrays, which have been successfully employed to identify novel SLE associated autoantibodies with reactivity in subgroups of SLE patients. [25] [26] [27] [28] [29] [30] [31] For example, Price et al. (2013) developed a cytokine array, which led to the identification of BAFF-binding autoantibodies in SLE. 32 While planar arrays have demonstrated great utility in the discovery of autoantibodies, their utility to serve as high quality, and especially diagnostic grade, clinical assays is still hampered by many technical limitations such as batch-to-batch and intra-array variability. 33 Multiparametric detection of autoantibodies in SLE P Budde et al. Figure 3 Heat map of cumulated 86 autoantibody reactivities in each cluster. The heat map colour is related to the absolute number of autoantibodies present in the investigated sample clusters. The intensity ranges from none (blue) to high (red). In addition, a hierarchical cluster analysis utilizing the Support-tree algorithm (Manhattan distance) was used to group antigens.
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In this study, we have used a multiplex beadbased array of 86 antigens to characterize autoantibody reactivity signatures in SLE patients. The array includes several novel autoantibody reactivities against nuclear and DNA-and RNA-binding proteins, which occur at high prevalence in this study cohort. However, further specificity testing, including autoimmune disease controls, is required to evaluate their diagnostic utility. We also present several novel autoantibody targets playing a role in immune/defense and apoptotic pathways matching the current hypothesis that proteins derived from NETs are strong autoantigens in SLE. Interestingly, one novel marker NCF2, which is component of the multi-protein NADPH oxidase (NADPHO) in phagocytic leukocytes, derives from an SLE susceptibility gene. 34, 35 As illustrated in this study, through expanding the current antigen repertoire by novel SLE-associated antigens and qualitative data analyses, we were able distinguish at least five distinct clusters of SLE patients. In general, the five clusters share a portfolio of autoantibody reactivities but also provide insight into some cluster-driving autoantibody markers as characteristic landmarks of each cluster. Interestingly, and serving as a confirmation for the validity of our findings, cluster ''red'' includes the highest number of patients with reactivity towards TRIM21 (SSA/Ro52) and TROVE2 (SSA/Ro60), which matches previous findings by Ching et al. (2012) , who found separate autoantibody clusters in SLE patients positive for Sm/RNP and Ro/La. 26 The cluster analysis also points to more subtle differences between clusters. For example, cluster ''red'' can be characterized by autoantibody reactivity towards neutrophilic granule (ANCA) and immune defense proteins when compared to all other clusters. Interestingly, two autoantibody reactivities with high frequency in the ''red'' cluster, HNRNPM and NONO/NRB54, are components of paraspeckles that are RNA-protein structures found in the interchromatin space of mammalian cells. Paraspeckles are critical for gene expression and may have a role during viral infection and stress response. 36 In contrast, cluster ''blue'', in which the largest number of patients with GLMN were found (n ¼ 14, 67%), a large percentage of SLE patients tested positive for antibodies to dsDNA, RPLP2 (ribosomal P) and SmD3. While it is generally accepted that anti-dsDNA antibodies have an association and also a pathogenic role in nephritis, the clinical association of ribosomal P and anti-Sm with nephritis has been described but is less well defined. 37, 38 Remarkably, novel autoantibody targets playing a role in apoptotic pathways (HIP1, FAF1, HSPE1) and inflammation (IL-6) were identified. The enriched antibody responses to apoptotic proteins and IL-6 (a prominent drug target in SLE drug development) may indicate that dysregulated processes of cellular damage in GLMN can generate additional sources of antigens. 39 Our study has several limitations as the sample size is relatively small, no autoimmune disease controls were included and differences in ethnicity were not considered. In future studies we plan to examine if autoantibody reactivity patterns in SLE patients remain stable over time or tend to fluctuate, such as anti-dsDNA titers. As the SLE study cohort was recruited in Germany, it will be important to evaluate how autoantibody reactivity patterns are affected by different ethnicities or different geographic regions. Another area with great demand for biomarkers for patient subgrouping is clinical trials. It will be interesting to see if patient clusters can be matched to certain responder populations.
Conclusions
Although the autoantibody repertoire in SLE appears to be highly diverse, our approach to analyze the autoantibody reactivity using multiparametric detection of 86 antigens enabled us to display common, overlapping and distinct autoantibody reactivity signatures in SLE patients. Patients grouped in two clusters have high signature reactivity and were more frequently diagnosed to have GLMN compared to other clusters. Thus, autoantibody profiling using bead-based antigen array appears to be a viable approach for identifying patient subgroups. Validation studies of the identified landmark antigens driving cluster formation will provide evidence whether they will support the distinguishing of basic patient cohorts and can be matched to differences in the SLE etiology, enabling them to be utilized in personalized medicine approaches.
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